A Pharma Video Quality Scorecard Beyond Completion Rate
Evaluate pharma video using valid delivery, placement, viewability, audibility, suitability, frequency, audience quality, and outcomes.
The short answer
A high completion rate can reflect engaged viewing, unskippable placement, autoplay, short duration, or invalid activity. Evaluate it alongside valid delivery, placement, viewability, audibility, suitability, frequency, audience quality, cost, and business outcomes.
Build a layered scorecard
| Layer | Metrics | Decision |
|---|---|---|
| Validity | Invalid traffic, app/domain identity | Was the opportunity legitimate? |
| Opportunity | Viewability, screen coverage, duration | Could a person see it? |
| Experience | Audibility, autoplay, controls, pod | What was the viewing context? |
| Suitability | Content category, adjacency, geography | Was the environment approved? |
| Audience | Eligible reach, match, composition | Did it reach the intended group? |
| Saturation | Frequency distribution, duplication | Was delivery wasteful? |
| Outcome | Brand, action, attributed or incremental Rx | Did it support the business objective? |
Use MRC definitions and accredited measurement where appropriate, while confirming that the specific vendor, product, format, and metric are within scope (MRC). Accreditation is not a blanket endorsement of every output.
Normalize before comparing
Compare the same video duration, skippability, device class, and placement type. A six-second unit and a 60-second unit should not be ranked on raw completion. Segment CTV from browser video and instream from other placements.
Use failure gates and diagnostic weights
Invalid or unauthorized supply may be a failure gate. Viewability and completion can be weighted diagnostics. Outcome evidence should remain separately labeled because a composite “quality score” can hide a commercially poor result.
Hypothetical example
Partner A has 96% completion but concentrated household frequency and weak app transparency. Partner B has 82% completion, broader qualified reach, and clearer supply. Completion alone favors A; the full scorecard may favor B. Figures are illustrative.
How to put the scorecard to work
A scorecard only helps if it changes buying decisions. Three habits make that happen.
Score at the level you can act on. A partner-level score is useful for renewal. A placement or app-level score is useful for weekly optimization. Build both from the same underlying data so they never disagree.
Refresh on a fixed schedule. Monthly is usually enough for partner scores; weekly for placement-level gates like invalid traffic or unauthorized sellers. Record the date on every score so nobody compares a June score with a September one.
Publish the gates to partners. Tell video partners in advance which metrics are hard gates and which are diagnostics. Partners who know that an unauthorized reseller path fails the scorecard regardless of completion rate will usually clean up supply before you have to ask.
A common failure is letting the scorecard become a single blended number in a quarterly deck. Keep the layers visible. A partner with excellent validity and suitability but weak audience reach needs a different conversation than a partner with the reverse. For the supply side of that conversation, see how to audit a CTV supply chain.
Practical takeaway
Do not collapse all evidence into one vanity index. The next step is a scorecard with hard gates, comparable diagnostic metrics, and a separate business-outcome panel.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.